Dr. Lin's lab is actively developing novel radiopharmaceuticals to improve cancer diagnosis and therapy. Current research efforts focus on (1) the development of novel radiopharmaceuticals targeting various potential markers expressed on cancer cell membranes; (2) the application of albumin binder to improve tumor uptake of radiotherapeutic agents; and (3) the application of cleavable linkers to reduce kidney uptake of peptide radiopharmaceuticals. 

Dr. Kuo-Shyan Lin's Research Gate Profile




Cynthia Ferguson

Research Projects and Operations Leader

Jinhe Pan

Research Assistant


Chao-Cheng (Jimmy) Chen

Post Doctoral Fellow

Sheetal Pathania

Postdoctoral Fellow

Fatemeh Radnia

Postdoctoral Fellow


Shreya Bendre

Graduate Student

Shireen Jozi

Graduate Student

Lei Wang

Graduate student

Selected Publications


Development of Receptor-targeting Radiopharmaceuticals

Various membrane receptors overexpressed in cancers are potential targets for diagnosis and therapy. These receptors include folate receptor, gastrin-releasing peptide receptor (GRPR), somatostatin receptor type 2 (Sstr2), C-X-C chemokine receptor type 4 (CXCR4) and melanocortin 1 receptor (MC1R). Our lab is actively developing radiopharmaceuticals targeting these receptors to improve diagnosis and radiotherapy of cancer.

Development of FAP-targeting Radiopharmaceuticals

Fibroblast activation protein (FAP), a transmembrane serine protease, is overexpressed in cancer associated fibroblasts (CAFs) in the stromal component of most carcinomas. Due to its absence or low expression level in normal tissues, FAP represents a promising cancer diagnostic marker and therapeutic target. Our lab is actively exploring the use of radiolabeled FAP-targeting pharmacophores for imaging and radiotherapy of cancer.

Cleavable Linkers to Reduce Kidney Uptake of Peptide Radiopharmaceuticals

Radiolabeled peptides are promising pharmaceuticals for cancer diagnosis and therapy. However, high kidney uptake of peptide radiopharmaceuticals is frequently observed due to specific and/or nonspecific interactions. High kidney uptake of radiopharmaceuticals hinders the detection of cancer lesions adjacent to kidneys, and reduces the therapeutic dose which can be safely administered into patients. 


Back to top